Advertisement

Lapatinib: New Directions in HER2 Directed Therapy for Early Stage Breast Cancer

  • A. Jo Chien
  • Hope S. Rugo
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

Introduction

Research over the last 20 years has resulted in the discovery of a wealth of information with regard to the biology of HER2 and the HER family, as well as convincing evidence supporting the HER2 oncogene hypothesis in the pathogenesis of human breast cancer. HER2 overexpressing tumors are highly addicted to HER2 function and undergo apoptotic cell death if HER2 function is lost. Approximately 25–30% of breast cancers overexpress HER2; clinically these tumors have been shown to have a more aggressive tumor biology and are associated with a worse clinical prognosis [1, 2] (although this has been modified by the use of chemotherapy and targeted therapies). Therefore, HER2 has become one of the most attractive targets in cancer therapeutics.

Efforts to develop HER2-inhibitors have primarily focused on two classes of drugs. The first includes monoclonal antibodies like trastuzumab that bind to the extracellular domain of the HER2 receptor. As discussed in the previous chapter,...

Keywords

Breast Cancer Brain Metastasis Inflammatory Breast Cancer Pathologic Complete Response Weekly Paclitaxel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes CJ, Kumar R. Biology of the epidermal growth factor receptor family. Cancer Treat Res. 2004;119:1–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Sliwkowski MX. Ready to partner. Nat Struct Biol. 2003;10(3):158–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977—84.PubMedCrossRefGoogle Scholar
  7. 7.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65(2):473–82.PubMedGoogle Scholar
  12. 12.
    Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99(6):783–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628–38.PubMedCrossRefGoogle Scholar
  14. 14.
    Anido J, Scaltriti M, Bech Serra JJ, et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. Embo J. 2006;25(13):3234–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Saez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006;12(2):424–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem. 1991;266(3):1716–20.PubMedGoogle Scholar
  17. 17.
    Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10(5):1618–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93(24):1852–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65(23):11118–28.PubMedCrossRefGoogle Scholar
  21. 21.
    Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3 K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat. 2005;91(2):187–201.PubMedCrossRefGoogle Scholar
  22. 22.
    Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–27.PubMedCrossRefGoogle Scholar
  23. 23.
    Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res. 2005;304(2):604–19.PubMedCrossRefGoogle Scholar
  24. 24.
    Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002;62(11):3151–8.PubMedGoogle Scholar
  25. 25.
    Valabrega G, Montemurro F, Sarotto I, et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene. 2005;24(18):3002–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Anastasi S, Sala G, Huiping C, et al. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene. 2005;24(28):4540–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21(41):6255–63.PubMedCrossRefGoogle Scholar
  28. 28.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene. 1989;4(10):1175–83.PubMedGoogle Scholar
  29. 29.
    Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005;16(11):1772–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26(18):2999–3005.PubMedCrossRefGoogle Scholar
  31. 31.
    Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Geyer CE, Martin A, Newstat B, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. . J Clin Oncol. 2007;25(18S):1035.Google Scholar
  33. 33.
    Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Lin N, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol. 2007;25(18S):1012.Google Scholar
  35. 35.
    Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys. 2004;58(2):344–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005;24(41):6213–21.PubMedCrossRefGoogle Scholar
  37. 37.
    Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007;6(2):667–74.PubMedCrossRefGoogle Scholar
  39. 39.
    Xia W, Husain I, Liu L, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007;67(3):1170–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol. 2005;23(S16):3004.Google Scholar
  41. 41.
    Iwata H, Toi M, Fujiwara Y, et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006;106:1091.Google Scholar
  42. 42.
    Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008;19(6):1068–74.PubMedCrossRefGoogle Scholar
  43. 43.
    DiLeo A, Gomez H, Aziz Z, et al. Lapatinib with paclitaxel versus paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study in 580 patients. J Clin Oncol. 2007;25(18S):1011.Google Scholar
  44. 44.
    Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 trial. Cancer Res. 2009; 69(Suppl.)46.Google Scholar
  45. 45.
    Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2008;26(20):3317–23.PubMedCrossRefGoogle Scholar
  46. 46.
    O’Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008;26:1015.CrossRefGoogle Scholar
  47. 47.
    Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10(5):1706–16.PubMedCrossRefGoogle Scholar
  48. 48.
    Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat. 2006;100(S1):301.Google Scholar
  49. 49.
    Rugo HS, Franco S, Munster P, et al. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). J Clin Oncol. 2008;26:1042.Google Scholar
  50. 50.
    Slamon D, Gomez HL, Kabbinawar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. J Clin Oncol. 2008;26:1016.CrossRefGoogle Scholar
  51. 51.
    Slamon DJ, Stemmer SM, Johnston S, et al. Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer. Cancer Res. 2009;69(Suppl.):4114.Google Scholar
  52. 52.
    Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. 2008;26(7):1066–72.PubMedCrossRefGoogle Scholar
  53. 53.
    Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat. 2006;106:1.Google Scholar
  54. 54.
    Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12(7):756–65.PubMedCrossRefGoogle Scholar
  55. 55.
    Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proceedings 2008;83(6):679–86.PubMedGoogle Scholar
  56. 56.
    Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378(6555):394–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459–65.PubMedCrossRefGoogle Scholar
  58. 58.
    Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Smith KL, Dang C, Seidman AD. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf. 2006;5(5):619–29.PubMedCrossRefGoogle Scholar
  60. 60.
    Midgley RS, Kerr DJ, Flaherty KT, et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol. 2007;18(12):2025–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Dang CT, Lin NU, Lake D, et al. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). J Clin Oncol. 2008;26:518.Google Scholar
  62. 62.
    Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019–27.PubMedCrossRefGoogle Scholar
  63. 63.
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–85.PubMedGoogle Scholar
  64. 64.
    van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224–37.PubMedGoogle Scholar
  65. 65.
    Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21(13):2600–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.University of California San FranciscoHelen Diller Family Comprehensive Cancer CenterSan FranciscoUS

Personalised recommendations